At Vincere Biosciences, our cutting-edge research focuses on the vital role of mitophagy in both Parkinson's disease and the aging process. By addressing deficient mitophagy, we can usher in a new era of groundbreaking treatments.
Our innovative pipeline consists of small molecules designed to boost mitophagy, with the potential to become the first-ever medicines capable of slowing or stopping Parkinson's disease and other age-related conditions.
By harnessing the power of our advanced research, we aim to bring hope and transform the lives of those affected by these debilitating diseases.
Supported by expert agencies such as the Michael J. Fox Foundation, the National Institute on Aging, and the National Institute on Neurological Disorders & Stroke, we have attracted top talent to drive our projects forward. As a resident of Johnson & Johnson Innovation - JLABS and recipient of a golden ticket award from Bristol Myers Squibb, we are well-positioned to advance our small molecules towards clinical translation.
We are committed to meeting aggressive timelines and delivering transformative solutions for age-related diseases, and welcome the opportunity to engage with investors, employees, and partners who share our vision and values. At Vincere Bio, we believe in extending healthy lifespan and improving human health.
Together, we can make a difference.